NEW YORK – Hamburg, Germany-based Indivumed on Thursday announced that it has expanded its global network of cancer centers and research institutions, allowing it to further build out its multiomics IndivuType database to advance precision oncology research.
Specifically, six large clinical systems across Asia, Europe, and South America will join Indivumed's Oncology Alliance for Individualized Medicine (Onco AI-Med), which is a partnership between cancer clinics and research institutions selected based on their expertise in molecularly informed cancer care. According to Indivumed, the additional sites are known for their excellence in basic and translational oncology research.
As part of Indivumed's global network, the new sites will contribute and have access to the IndivuType database, which includes a biobank of patient samples and associated genomic, transcriptomic, proteomic, immuno-phenotypic, digital histopathology, and clinical data. All of this information is integrated using Indivumed's advanced artificial intelligence technology.
The network sites will contribute samples and datasets to IndivuType database employing Indivumed's proprietary standardized process. Using the information in the database, participating sites will conduct joint research projects using multiomics approaches to advance personalized cancer therapy.
"Partnering with leading clinics globally gives us the ability to gather large quantities of reproducible data, which can be compared from patient to patient, between tumor entities, and also geographic regions because they have all adhered to the same stringent processes of tissue collection and data processing," Hartmut Juhl, Indivumed's CEO and founder, said in a statement. "The continued growth of the Indivumed clinical network, including now a strong presence in Asia, allows us to offer an extensive stratification of patient samples that are of the highest quality to clinical trials around the world."
With the addition of the six new sites, Indivumed's network now spans more than 30 clinical systems from 10 countries and four continents, and the company expects to grow its database with up to 10,000 new datasets per year.